The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.
GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Pharmaceutical Technology on MSN15d
GSK to acquire Chimagen’s CMG1A46 for autoimmune diseaseGlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...
GlaxoSmithKline (GSK ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more. In the age of AI, large data sets ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback